6MU-62250-41376

3 vaccinations 18 coded responses 26 check-ins 18 free-text entries 3 call cases

Sex: —
Age at first dose: 31-35
ZIP prefix: 300 / GA
Registered: 2021-01-24

Relationship: Self
Race: White
Ethnicity: Not Hispanic or Latino

Timeline

Registration Vaccinations Survey responses Call reports Cases without a report Call attempts Call successful Pregnancy survey

2021-01-24
Registered in v-safe
2021-01-24
Dose 1 — Moderna
2021-01-24
Health check-in — day 0, dose 1
Feeling: Good · None

Adult check-in
2021-01-25
Survey response — days 1–6 daily, dose 1
MedDRA: Vitreous floaters — Feeling: Fair · Site: Pain, Swelling, Itching · Headache, Muscle or body aches, Fatigue or tiredness · Be unable to work, Be unable to do your normal daily activities

Free text: Vision floaters

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-01-26
Survey response — days 1–6 daily, dose 1
MedDRA: Vitreous floaters — Feeling: Good · Site: Pain, Redness, Swelling, Itching · Muscle or body aches · Be unable to do your normal daily activities

Free text: Vision static/floaters

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-01-27
Survey response — days 1–6 daily, dose 1
MedDRA: Vitreous floaters — Feeling: Good · Site: Pain, Redness, Swelling

Free text: Visual floaters/static (mild)

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-01-28
Survey response — days 1–6 daily, dose 1
MedDRA: Vitreous floaters — Feeling: Good · Site: Redness, Swelling

Free text: Floaters in eye

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-01-29
Survey response — days 1–6 daily, dose 1
MedDRA: Visual impairment — Feeling: Good · Site: Redness

Free text: Vision floaters

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-01-31
Survey response — day 7, dose 1
MedDRA: Vitreous floaters — Feeling: Good · Site: Redness

Free text: Vision floaters

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-02-07
Survey response — day 14, dose 1
MedDRA: Fatigue, Injection site discolouration, Injection site erythema, Injection site irritation, Injection site pruritus, Injection site swelling, Musculoskeletal stiffness, Skin irritation — Feeling: Fair · Be unable to work, Be unable to do your normal daily activities

Free text: Fatigue, extreme itch on injection site, purple circle in the middle of injection sitez raised, red, and irritated skin on injection site, very stiff muscles

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-02-14
Health check-in — day 21, dose 1
Feeling: Fair

Adult check-in
2021-02-21
Dose 2 — Moderna
2021-02-21
Survey response — day 0, dose 2
MedDRA: Peripheral swelling, Vitreous floaters — Feeling: Fair · Site: Pain, Redness, Swelling, Itching · Fever · Chills, Joint pains, Muscle or body aches, Rash, not including the immediate area around the injection site · Be unable to work, Be unable to do your normal daily activities

Free text: Slightly swollen fingers, part of hand. Eye floaters

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-02-22
Survey response — days 1–6 daily, dose 2
MedDRA: Vitreous floaters — Feeling: Poor · Site: Pain, Redness, Swelling · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to work, Be unable to do your normal daily activities

Free text: Eye floaters

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-02-25
Survey response — days 1–6 daily, dose 2
MedDRA: Vitreous floaters — Feeling: Fair · Site: Pain, Redness, Swelling, Itching · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to do your normal daily activities

Free text: Eye floaters

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-03-06
Survey response — day 7, dose 2
MedDRA: Vitreous floaters — Feeling: Good · Site: Redness, Itching · Headache, Fatigue or tiredness, Nausea · Be unable to work, Be unable to do your normal daily activities

Free text: Eye floaters

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-03-13
Health check-in — day 14, dose 2
Feeling: Fair

Adult check-in
2021-03-14
Survey response — day 21, dose 2
MedDRA: Fatigue, Pyrexia, Vitreous floaters — Feeling: Fair · Be unable to work, Be unable to do your normal daily activities

Free text: Eye floaters, fatigue, fever

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-03-23
Health check-in — day 28, dose 2
Feeling: Good

Adult check-in
2021-04-04
Survey response — day 42, dose 2
MedDRA: Ageusia — Feeling: Good

Free text: Loss of taste, taste is off

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-05-23
Survey response — 3 months, dose 2
MedDRA: Ageusia, Taste disorder, Vitreous floaters — Feeling: Fair · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation

Free text: Occasional loss of taste/altered tasteEye floaters

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-05-23
Report sent to call center — 3 months, dose 2
Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional

1 call case(s)
2021-08-24
Survey response — 6 months, dose 2
MedDRA: Condition aggravated, Inflammation, Intracranial pressure increased, Medical counselling, Pre-existing disease — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visit

Free text: Symptoms: Intercranial Hypertension, inflammation, triggered autoimmune disorders · Healthcare visit (other): Specialist center testing

MedDRA releases: 2021-09,2024-11 · check-in free text available
2021-08-24
Report sent to call center — 6 months, dose 2
Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare pr

1 call case(s)
2021-08-27
Call 1 — Left Voicemail
2021-08-27
Call 1 — Left Voicemail
2021-11-11
Dose 3 — Moderna
2021-11-13
Health check-in — days 1–6 daily, dose 3
Feeling: Poor · Site: Pain, Redness, Swelling, Itching · Fever · Chills, Headache, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to work or attend school, Be unable to do your normal daily activities

Adult check-in
2021-11-15
Health check-in — days 1–6 daily, dose 3
Feeling: Fair · Site: Pain, Redness, Swelling, Itching · Headache, Fatigue or tiredness · Be unable to work or attend school, Be unable to do your normal daily activities

Adult check-in
2021-11-16
Survey response — days 1–6 daily, dose 3
MedDRA: Vitreous floaters — Feeling: Fair · Site: Pain, Redness, Swelling, Itching · Headache, Fatigue or tiredness, Diarrhea · Be unable to work or attend school, Be unable to do your normal daily activities

Free text: Eye floaters

MedDRA releases: 2024-11 · check-in free text available
2021-11-17
Survey response — days 1–6 daily, dose 3
MedDRA: Vitreous floaters — Feeling: Fair · Site: Redness, Swelling, Itching · Headache, Fatigue or tiredness, Diarrhea · Be unable to work or attend school, Be unable to do your normal daily activities

Free text: Eye floaters

MedDRA releases: 2024-11 · check-in free text available
2021-11-25
Health check-in — day 14, dose 3
Feeling: Fair

Adult check-in
2022-02-12
Health check-in — 3 months, dose 3
Feeling: Fair

Adult check-in
2022-11-11
Survey response — 12 months, dose 3
MedDRA: Autoimmune disorder, Butterfly rash, Condition aggravated, Fatigue, Intracranial pressure increased, Pre-existing disease, Pyrexia, Tachycardia — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit, Emergency room or emergency department visit

Free text: Worsened myalgic encephalopathy, horrinle fatigue, tachycardia, mylar rash, fever symptoms, autoimmune disorder, intercranial hypertension

MedDRA releases: 2024-11 · check-in free text available
2022-11-11
Report sent to call center — 12 months, dose 3
Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare pr

Outpatient clinic or urgent care clinic visit · Emergency room or emergency department visit · 1 call case(s)
2022-11-14
Call 2 — Left Voicemail
2022-11-14
Call 2 — Left Voicemail
2022-11-14
Call 1 — Left Voicemail

Vaccinations

Dose	Date	Manufacturer	Co-administered
1	2021-01-24	Moderna
2	2021-02-21	Moderna
3	2021-11-11	Moderna	No

Call center

3 call center cases

3 unsuccessful

1 wait over 3 months for a first call

See the call center timeline

Free text

Release 2 — days 1–6 daily, dose 1

2021-01-25

Systemic reaction (other): Vision floaters

2021-01-26

Systemic reaction (other): Vision static/floaters

2021-01-27

Systemic reaction (other): Visual floaters/static (mild)

2021-01-28

Systemic reaction (other): Floaters in eye

Release 3 — days 1–6 daily, dose 1

2021-01-29

Systemic reaction (other): Vision floaters

Release 3 — day 7, dose 1

2021-01-31

Systemic reaction (other): Vision floaters

Release 3 — day 14, dose 1

2021-02-07

Symptoms: Fatigue, extreme itch on injection site, purple circle in the middle of injection sitez raised, red, and irritated skin on injection site, very stiff muscles

Release 4 — day 0, dose 2

2021-02-21

Systemic reaction (other): Slightly swollen fingers, part of hand. Eye floaters

Release 4 — days 1–6 daily, dose 2

2021-02-22

Systemic reaction (other): Eye floaters

2021-02-25

Systemic reaction (other): Eye floaters

Release 5 — day 7, dose 2

2021-03-06

Systemic reaction (other): Eye floaters

Release 5 — day 21, dose 2

2021-03-14

Symptoms: Eye floaters, fatigue, fever

Release 6 — day 42, dose 2

2021-04-04

Symptoms: Loss of taste, taste is off

Release 8 — 3 months, dose 2

2021-05-23

Symptoms: Occasional loss of taste/altered tasteEye floaters

Release 9 — 6 months, dose 2

2021-08-24

Symptoms: Intercranial Hypertension, inflammation, triggered autoimmune disorders

Healthcare visit (other): Specialist center testing

Release 10 — days 1–6 daily, dose 3

2021-11-16

Systemic reaction (other): Eye floaters

2021-11-17

Systemic reaction (other): Eye floaters

Release 12 — 12 months, dose 3

2022-11-11

Symptoms: Worsened myalgic encephalopathy, horrinle fatigue, tachycardia, mylar rash, fever symptoms, autoimmune disorder, intercranial hypertension

Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".

MedDRA terms by release

Field	Preferred term	2021-09	2023-04	2024-11
HCVO	Medical counselling	✓	·	✓
SD	Ageusia	✓	✓	✓
SD	Autoimmune disorder	·	·	✓
SD	Butterfly rash	·	·	✓
SD	Condition aggravated	✓	·	✓
SD	Fatigue	✓	✓	✓
SD	Inflammation	✓	·	✓
SD	Injection site discolouration	✓	✓	✓
SD	Injection site erythema	✓	✓	✓
SD	Injection site irritation	✓	✓	✓
SD	Injection site pruritus	✓	✓	✓
SD	Injection site swelling	✓	✓	✓
SD	Intracranial pressure increased	✓	·	✓
SD	Musculoskeletal stiffness	✓	✓	✓
SD	Pre-existing disease	✓	·	✓
SD	Pyrexia	✓	✓	✓
SD	Skin irritation	✓	✓	✓
SD	Tachycardia	·	·	✓
SD	Taste disorder	✓	✓	✓
SD	Vitreous floaters	✓	✓	✓
SRO	Peripheral swelling	✓	✓	✓
SRO	Visual impairment	✓	✓	✓
SRO	Vitreous floaters	✓	✓	✓

✓ active code · ○ coded but marked inactive · blank = not in that release